

30th April 2024

The Manager-Listing BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 The Manager- Listing National Stock Exchange of India Ltd., Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

- Sub: Intimation of Board Meeting to consider Audited Financial Results of the Company for the 4th quarter and financial year ended 31st March 2024 and to consider recommendation of Dividend for the financial year 2023-24, if any.
- Ref: Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 29 and 33 of the Listing Regulations 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday, 08th May 2024 to approve the following.

- 1. To consider, approve and take on record Audited Financial Results (Standalone and Consolidated) of the Company for the 4th quarter and year ended 31st March 2024.
- 2. To consider recommendation of Dividend for the year 2023-24, if any subject to Approval of shareholders in ensuing AGM.
- 3. To decide the date of Annual General Meeting of the Company.
- 4. Any other business with the permission of board.

The Company has already closed its "Trading Window" under the Code of Conduct for prevention of Insider Trading from 31st March 2024 and it will re-open on 11th May 2024.

You are requested to take note of the above.

Thanking You.

Yours faithfully, For Nath Bio-Genes (India) Limited,

Devinder Khurana Chief Financial Officer

 Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7 Email : info@nathseeds.com www.nathbiogenes.com

1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5